Tenax Therapeutics listed on Nasdaq and received research reports from Cantor Fitzgerald, attracting investment from ADAR1 Capital Management.
4 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tenax Therapeutics listed on Nasdaq and received research reports from Cantor Fitzgerald, attracting investment from ADAR1 Capital Management.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Nasdaq
American fully electronic stock exchange
Related events
- Cantor Fitzgerald provided research reports on Cabaletta Bio, a company whose stock trades on Nasdaq.
- Generate Biomedicines Inc listed its shares on the Nasdaq exchange and received research notes and ratings from Cantor Fitzgerald.
- Analyst provides a high price target for Viking Therapeutics stock.
- Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.